Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States
Maternal vaccination with RSVpreF would substantially reduce the clinical and economic burden of RSV in infants, resulting in a cost-effectiveness ratio of $89,733 per QALY if administered year-round or cost savings if administered seasonally.
Authors
- Kimberly M. Shea (ORCID: https://orcid.org/0000-0002-8760-5357)
- Derek Weycker (ORCID: https://orcid.org/0000-0002-5405-2215)
- Ahuva Averin (ORCID: https://orcid.org/0000-0002-4490-7021)
- Mark Atwood
- Amy Law
- Erin Quinn
Institutions
- Pfizer (United States) (US)
- Prevea Health (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127191
- Citations
- 5
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 6.77
Funders
- Pfizer